Neurocrine Biosciences Financials - Benzinga

Neurocrine Biosciences Inc

NBIXNASDAQ

Trade with Public

Trade with Public

$138.40

-0.54-0.39%

In chiusura: Sep 25, 5:00 PM EST

$138.40

N/A

Post-mercato: Sep 25, 4:30 PM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Neurocrine Biosciences Financials

Neurocrine Biosciences (NBIX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the analyst consensus estimate of $1.34 by 112.69 percent. This is a 72.73 percent increase over earnings of $1.65 per share

Benzinga Newsdesk

PRO
Neurocrine Biosciences Q1 Adj. EPS $1.94 Beats $1.61 Estimate, Sales $814.500M Beat $763.112M Estimate

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.94 per share which beat the analyst consensus estimate of $1.61 by 20.5 percent. This is a 177.14 percent increase over earnings of $0.70 per share

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Neurocrine shares fell 8% after mixed earnings, strong Ingrezza sales, and a 2026 outlook that met expectations. Analysts see long-term upside despite short-term pressure.

Vandana Singh

Neurocrine Biosciences Q4 Earnings Assessment

Benzinga Insights

PRO
Neurocrine Biosciences Expects FY26 INGREZZA Net Product Sales Of $2.70B-$2.80B

Full-Year 2026 Financial Guidance Range(in millions)Low HighINGREZZA Net Product Sales 1$ 2,700 $

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved